Abstract
Cannabis is a plant with a long history of human pharmacological use, both for recreational purposes and as a medicinal remedy. Many potential modern medical applications for cannabis have been proposed and are currently under investigation.
As the use of medicinal cannabis has gained significant attention over the past few years, it is essential to understand phytocannabinoid disposition within the human body, and especially their metabolic pathways. A more thorough understanding of the complex metabolism of phytocannabinoids generates many opportunities, especially regarding possible drug-drug interactions (DDIs).
Within this context, computer simulations are commonly used for predicting substrates and inhibitors of metabolic enzymes. These predictions can assist in identifying metabolic pathways by understanding individual CYP isoform specificities to a given molecule, which can help to predict potential enzyme inhibitions and DDIs.
During the hour, we’ll cover:
– The reported in vivo Phase I and Phase II metabolisms of various phytocannabinoids will be reviewed
– In silico analysis of their predicted metabolism
– Highlighting the clinical importance of such understanding in terms of DDIs and clinical outcomes
Presenters:
Daniela Amaral Silva, Raimar Loenberg
Faculty of Pharmacy & Pharmaceutical Sciences, University of Alberta
Panelist:
Robert D. Clark
Sr. Research Fellow, Simulations Plus, Inc.
The webinar is based on the recent publication: Phytocannabinoid drug-drug interactions and their clinical implications